- Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS Yahoo Finance
- Geron Stock Is Soaring After Hours: What’s Going On? Yahoo Finance
- Geron’s stock soars 95% after FDA panel votes in favor of blood-disorder drug MarketWatch
- Geron triumphs in FDA AdComm battle, securing 12-2 vote in favor of blood cancer drug imetelstat Fierce Biotech
- Imetelstat improves blood transfusion independence in lower-risk myelodysplastic syndromes 2 Minute Medicine
Read More: Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the